{"id":2072,"date":"2026-09-25T19:08:09","date_gmt":"2026-09-25T10:08:09","guid":{"rendered":"https:\/\/globalregulatorypartners.co.jp\/?post_type=news&p=2072"},"modified":"2026-09-25T19:21:27","modified_gmt":"2026-09-25T10:21:27","slug":"global-regulatory-partners-to-exhibit-at-biojapan-2026","status":"publish","type":"news","link":"https:\/\/globalregulatorypartners.co.jp\/en\/news\/global-regulatory-partners-to-exhibit-at-biojapan-2026\/","title":{"rendered":"Global Regulatory Partners to Exhibit at BioJapan \u00a02026"},"content":{"rendered":"\n

Connecting innovation with markets in Japan and worldwide<\/em><\/p>\n\n\n\n

October 7-9, 2026  |  PACIFICO Yokohama  |  Booth C-41<\/strong><\/p>\n\n\n\n

Link to Document HERE<\/a><\/strong><\/p>\n\n\n\n

Tokyo, Japan \u2013<\/strong> September 25, 2026<\/strong> – Global Regulatory Partners (GRP)<\/strong> is pleased to announce its participation in BioJapan<\/strong> <\/strong> 2026<\/strong>, where GRP will exhibit at Booth C-41 and participate in the event’s international Partnering program.<\/p>\n\n\n\n

BioJapan<\/strong>  2026<\/strong> is observing its 40th anniversary<\/strong> as the world\u2019s longest running biotechnology event.  It is held together with concurrent events,Regenerative Medicine JAPAN<\/strong>, and healthTECH JAPAN<\/strong>, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.<\/p>\n\n\n\n

Helping global innovation reach Japan – and Japanese innovation reach the world<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

A Market-Entry Partner Built Around the Client<\/h1>\n\n\n\n

Bringing an innovative healthcare product to a new market requires more than regulatory approval. Companies must gain a deep understanding of the market and determine the right regulatory pathway, operating model, local partnerships, commercialization approach, and post-market structure for their product and business objectives.<\/p>\n\n\n\n

GRP helps overseas healthcare companies enter and operate in the Japanese market in the way best suited to their individual needs, taking into account the specific requirements of Japanese regulatory authorities. Our capabilities range from regulatory strategy and product registration to serving as Marketing Authorization Holder (MAH),<\/strong> as well as supporting quality, pharmacovigilance, medical information, market access, distribution, and other activities needed to establish and maintain products in Japan.<\/p>\n\n\n\n

This flexible approach allows overseas companies to build a Japan market-entry model appropriate to their product, stage of development, resources, and long-term strategy – without necessarily having to establish and maintain all required capabilities themselves.<\/p>\n\n\n\n

To make this possible, GRP has established a market-entry platform through which GRP Japan, as the MAH, supports clients from regulatory strategy through post-approval commercialization, helping maximize the return on investment of their market entry.<\/p>\n\n\n\n

GRP also works in the other direction. For Japanese companies seeking opportunities outside Japan, GRP provides access to regulatory expertise and support across international markets, helping companies evaluate pathways for overseas development and commercialization and connect Japanese healthcare innovation with patients and partners globally.<\/p>\n\n\n\n

Meet GRP at BioJapan  2026<\/h1>\n\n\n\n

Visitors are invited to meet the GRP team at Booth C-41<\/strong> and through the BioJapan<\/strong> <\/strong> Partnering<\/strong> program to discuss:<\/p>\n\n\n\n